Skip to content
Open access

Nationwide study of blood eosinophils in COPD: impact of exacerbations and corticosteroids

Oct 2026 · BMJ Open Respiratory Research · Vol 13 · 0 citations · 36 references
Medicine

TL;DR

Blood eosinophil counts in COPD are highly dynamic, with most patients shifting categories over time independent of clinical exposures; repeated assessments could improve identification of patients most likely to benefit from type 2 inflammation-targeted treatments.

Abstract

Abstract Introduction Blood eosinophils are increasingly used as biomarkers to guide inhaled corticosteroid (ICS) and biologic therapy in chronic obstructive pulmonary disease (COPD). However, the long-term stability of eosinophil count and the impact of proximate clinical events remain uncertain. This study examines the longitudinal stability of blood eosinophil counts in a nationwide cohort of COPD patients and identifies acute exposures temporally linked to eosinophil measurement variability. Methods We used routinely collected Danish national registry data including 63 517 patients with COPD aged ≥40 years with ≥4 eosinophil measurements during 2–6 years of follow-up (median 3.4). Eosinophils were categorised as <0.15, 0.15–0.29 and ≥0.30×10⁹/L. Logistic regression assessed associations between stability and clinical exposures, adjusting for baseline eosinophils, age, sex, comorbidities, oral corticosteroid (OCS) use, antibiotics and exacerbations. Transitions were visualised with Sankey diagrams. Results Overall, 26% of patients remained within the same eosinophil category across all repeated measurements (stable patient phenotype), while 74% experienced ≥1 category shift. Baseline eosinophils ≥0.30×10⁹/L predicted phenotypic stability (OR 1.70, 95% CI 1.63 to 1.77). Severe exacerbations, OCS and antibiotics prior to testing were associated with individual measurement variability, yet >80% of unstable measurements occurred without these exposures. Among patients with an unstable phenotype, 39.7% shifted once, 43.2% two times and 17.1% three times. Use of triple inhaler therapy (long-acting beta-agonist, long-acting muscarinic antagonist, ICS) was slightly more common among in the unstable group. Conclusions Blood eosinophil counts in COPD are highly dynamic, with most patients shifting categories over time independent of clinical exposures. Single eosinophil measurements may be unreliable for guiding therapy; repeated assessments could improve identification of patients most likely to benefit from type 2 inflammation-targeted treatments.

Read PDF

Similar papers

Open access Sep 2026

Blood eosinophils in COPD: are biologics for everyone?

Background: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation. Objectives: To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics. Design: Real-world, retrospective, monocentric study in...

M. Vanetti, Dina Visca, F. Ardesi et al. · 0 citations
Sep 2026

Tracking blood eosinophils over time: long-term trends in asthmatic patients from the COBRA cohort.

BACKGROUND In patients with asthma, long-term follow-up of blood eosinophil count (BEC) may be useful for identifying endotypes. The observational French COhort of BRonchial obstruction and Asthma (COBRA) study is an observational prospective multicenter cohort enrolling asthmatic patients. OBJECTIVE To compare clini...

M. Gueçamburu, Fanchon Herman, Joana Vitte et al. · 0 citations
Review Open access Sep 2026

Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP.

RATIONALE The efficacy of biologics remains debatable in current or ex- smokers with severe asthma. OBJECTIVES This study aimed to evaluate responses to biologics by smoking exposure and to assess variations in management practice across Europe. METHODS This was a retrospective real-world study of adults with sever...

M. Caminati, J. Charriot, A. Bansal et al. · 1 citation
Open access Sep 2026

Inflammatory discordance phenotype in COPD: Dissociation between neutrophil-to-lymphocyte ratio and conventional markers

Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder with diverse inflammatory profiles. Long-term oxygen therapy (LTOT) identifies a subgroup of patients with advanced disease; however, the systemic inflammatory characteristics of this population remain incompletely defined. Objective To...

Can Çolakoğlu, Sefa Levent Ozşahin · 0 citations
Open access Sep 2026

Multidimensional Inflammatory Biomarker Profiling in COPD: A Latent Inflammatory Construct Associated with Disease Severity and Exacerbation Burden

Background/Objectives: Systemic inflammation is a widely recognised feature of chronic obstructive pulmonary disease (COPD). The combined contribution of acute-phase reactants and pro-inflammatory cytokines to disease severity and exacerbation risk remains incompletely understood. This study evaluated the associations...

Oana Maria Catană, Ramona Cioboată, D. Mitroi et al. · 0 citations
Open access Oct 2026

Precision targeting of type 2 inflammation in COPD: identifying candidates for dupilumab therapy

Type 2 (T2) inflammation represents a clinically important and therapeutically tractable endotype in 20%–40% of patients with chronic obstructive pulmonary disease (COPD). This subgroup is characterised by elevated blood eosinophil counts, increased fractional exhaled nitric oxide (FeNO), and activation of the interleu...

Ke-Zhuo Zhong, Kai-Ying Lv, Qun Liang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.